[1] REUBEN A, KOCH D G, LEE W M. Drug-induced acute liver failure:results of a US multicenter, prospective study [J]. Hepatology, 2010, 52(6):2065-2076.
[2] TESCHKE R, ZHANG L, LONG H, et al. Traditional Chinese medicine and herbal hepatotoxicity:A tabular compilation of reported cases [J]. Ann Hepatol, 2015, 14(1):7-19.
[3] ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China:A systematic analysis of the Chinese literature including 21,789 patients [J]. Eur J Gastroenterol Hepatol, 2013, 25(7):825-829.
[4] AMACHER D E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs [J]. Regul Toxicol Pharmacol, 1998, 27(2):119-130.
[5] CHEN M, ZHANG J, WANG Y, et al. The liver toxicity knowledge base:A systems approach to a complex end point [J]. Clin Pharmacol Ther, 2013, 93(5):409-412.
[6] BJORNSSON E S, BERGMANN O M, BJORNSSON H K, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland [J]. Gastroenterology, 2013, 144(7):1419-1425.
[7] FONTANA R J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives [J]. Gastroenterology, 2014, 146(4):914-928.
[8] CHALASANI N P, HAYASHI P H, BONKOVSKY H L, et al. ACG Clinical guideline:the diagnosis and management of idiosyncratic drug-induced liver injury [J]. Am J Gastroenterol, 2014, 109(7):950-966.
[9] GULMEZ S E, LARREY D, PAGEAUX G P, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen):the multinational case-population SALT study [J]. Drug Saf, 2013, 36(2):135-144.
[10] CHEN M, BORLAK J, TONG W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury [J]. Hepatology, 2013, 58(1):388-396.
[11] KAPLOWITZ N. Avoiding idiosyncratic DILI:two is better than one [J]. Hepatology, 2013, 58(1):15-17.
[12] UETRECHT J P. New concepts in immunology relevant to idiosyncratic drug reactions:the "danger hypothesis" and innate immune system [J]. Chem Res Toxicol, 1999, 12(5):387-395.
[13] STEPAN A F, WALKER D P, BAUMAN J, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity:a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States [J]. Chem Res Toxicol, 2011, 24(9):1345-410.
[14] STEPHENS C, ANDRADE R J, LUCENA M I. Mechanisms of drug-induced liver injury [J]. Curr Opin Allergy Clin Immunol, 2014, 14(4):286-292.
[15] WILL Y, DYKENS J. Mitochondrial toxicity assessment in industry--a decade of technology development and insight [J]. Expert Opin Drug Metab Toxicol, 2014, 10(8):1061-1067.
[16] CHEN M, BISGIN H, TONG L, et al. Toward predictive models for drug-induced liver injury in humans:are we there yet? [J]. Biomark Med, 2014, 8(2):201-213.
[17] PARK B K, LAVERTY H, SRIVASTAVA A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity [J]. Chem Biol Interact, 2011, 192(1-2):30-36.
[18] OBACH R S, KALGUTKAR A S, SOGLIA J R, et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose [J]. Chem Res Toxicol, 2008, 21(9):1814-1822.
[19] PARK B K, BOOBIS A, CLARKE S, et al. Managing the challenge of chemically reactive metabolites in drug development [J]. Nat Rev Drug Discov, 2011, 10(4):292-306.
[20] LUCENA M I, ANDRADE R J, RODRIGO L, et al. Trovafloxacin-induced acute hepatitis [J]. Clin Infect Dis, 2000, 30(2):400-401.
[21] JAESCHKE H, MCGILL M R, RAMACHANDRAN A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury:lessons learned from acetaminophen hepatotoxicity [J]. Drug Metab Rev, 2012, 44(1):88-106.
[22] MORGAN R E, TRAUNER M, VAN STADEN C J, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development [J]. Toxicol Sci, 2010, 118(2):485-500.
[23] ALEO M D, LUO Y, SWISS R, et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump [J]. Hepatology, 2014, 60(3):1015-1022.
[24] KOCK K, FERSLEW B C, NETTERBERG I, et al. Risk factors for development of cholestatic drug-induced liver injury:inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4 [J]. Drug Metab Dispos, 2014, 42(4):665-674.
[25] FOUNTAIN F F, TOLLEY E, CHRISMAN C R, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection:a 7-year evaluation from a public health tuberculosis clinic [J]. Chest, 2005, 128(1):116-123.
[26] LUCENA M I, ANDRADE R J, KAPLOWITZ N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury:the influence of age and sex [J]. Hepatology, 2009, 49(6):2001-2009.
[27] CHALASANI N, FONTANA R J, BONKOVSKY H L, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States [J]. Gastroenterology, 2008, 135(6):1924-1934.
[28] EICHELBAUM M, INGELMAN-SUNDBERG M, EVANS W E. Pharmacogenomics and individualized drug therapy [J]. Annu Rev Med, 2006, 57:119-137.
[29] OSTERREICHER C H, SCHULTHEISS J, WEHLER M, et al. Genetic polymorphisms of manganese-superoxide dismutase and glutathione-S-transferase in chronic alcoholic pancreatitis [J]. Mutagenesis, 2007, 22(5):305-310.
[30] NG C S, HASNAT A, AL MARUF A, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group [J]. Eur J Clin Pharmacol, 2014, 70(9):1079-1086.
[31] HUNT C M, WESTERKAM W R, STAVE G M. Effect of age and gender on the activity of human hepatic CYP3A [J]. Biochem Pharmacol, 1992, 44(2):275-283.
[32] ZIMMERMAN H J, MADDREY W C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol:analysis of instances of therapeutic misadventure [J]. Hepatology, 1995, 22(3):767-773.
[33] YU K, GENG X, CHEN M, et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury [J]. Drug Metab Dispos, 2014, 42(4):744-750.
[34] LUCENA M I, GARCIA-MARTIN E, ANDRADE R J, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury [J]. Hepatology, 2010, 52(1):303-312.
[35] FROMENTY B. Drug-induced liver injury in obesity [J]. J Hepatol, 2013, 58(4):824-826.
[36] PAULI-MAGNUS C, MEIER P J. Hepatobiliary transporters and drug-induced cholestasis [J]. Hepatology, 2006, 44(4):778-787.
[37] DALY A K, DONALDSON P T, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J]. Nat Genet, 2009, 41(7):816-819.
[38] CHO J, KIM L, LI Z, et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice:suggested roles for Tregs, estrogen, and IL-6 [J]. PLoS One, 2013, 8(4):e61186.
[39] TOYODA Y, MIYASHITA T, ENDO S, et al. Estradiol and progesterone modulate halothane-induced liver injury in mice [J]. Toxicol Lett, 2011, 204(1):17-24.
[40] FONTANA R J, HAYASHI P H, GU J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset [J]. Gastroenterology, 2014, 147(1):96-108.
[41] DENG X, STACHLEWITZ R F, LIGUORI M J, et al. Modest inflammation enhances diclofenac hepatotoxicity in rats:role of neutrophils and bacterial translocation [J]. J Pharmacol Exp Ther, 2006, 319(3):1191-1199.
[42] NGUYEN G C, SAM J, THULUVATH P J. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States:a nationwide analysis [J]. Hepatology, 2008, 48(4):1336-1341.
[43] LOMTADZE N, KUPREISHVILI L, SALAKAIA A, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis [J]. PLoS One, 2013, 8(12):e83892.
[44] SHUKLA V, CUENIN C, DUBEY N, et al. Loss of histone acetyltransferase cofactor transformation/transcription domain-associated protein impairs liver regeneration after toxic injury [J]. Hepatology, 2011, 53(3):954-963.
[45] MURATA K, HAMADA M, SUGIMOTO K, et al. A novel mechanism for drug-induced liver failure:inhibition of histone acetylation by hydralazine derivatives [J]. J Hepatol, 2007, 46(2):322-329.
[46] POOYA S, BLAISE S, MORENO GARCIA M, et al. Methyl donor deficiency impairs fatty acid oxidation through PGC-1alpha hypomethylation and decreased ER-alpha, ERR-alpha, and HNF-4alpha in the rat liver [J]. J Hepatol, 2012, 57(2):344-351.
[47] VILLANUEVA J A, ESFANDIARI F, WHITE M E, et al. S-adenosylmethionine attenuates oxidative liver injury in micropigs fed ethanol with a folate-deficient diet [J]. Alcohol Clin Exp Res, 2007, 31(11):1934-1943.
[48] BROWN G R, PERSLEY K. Hepatitis A epidemic in the elderly [J]. South Med J, 2002, 95(8):826-833.
[49] SUZUKI A, YUEN N, WALSH J, et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury [J]. Clin Gastroenterol Hepatol, 2009, 7(8):882-888.
[50] JOG N R, CARICCHIO R. Differential regulation of cell death programs in males and females by Poly (ADP-Ribose) Polymerase-1 and 17beta estradiol [J]. Cell Death Dis, 2013, 4:e758.